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Abstract: Epigenetics refers to the heritable changes in gene expression without a change in the
DNA sequence itself. Two of these major changes include aberrant DNA methylation as well as
changes to histone modification patterns. Alterations to the epigenome can drive expression of
oncogenes and suppression of tumor suppressors, resulting in tumorigenesis and cancer progression.
In addition to modifications of the epigenome, microRNA (miRNA) dysregulation is also a hallmark
for cancer initiation and metastasis. Advances in our understanding of cancer biology demonstrate
that alterations in the epigenome are not only a major cause of miRNA dysregulation in cancer, but
that miRNAs themselves also indirectly drive these DNA and histone modifications. More explicitly,
recent work has shown that miRNAs can regulate chromatin structure and gene expression by directly
targeting key enzymes involved in these processes. This review aims to summarize these research
findings specifically in the context of breast cancer. This review also discusses miRNAs as epigenetic
biomarkers and as therapeutics, and presents a comprehensive summary of currently validated
epigenetic targets in breast cancer.
Keywords: non-coding RNAs; microRNAs; epigenetics; breast cancer
1. Non-coding RNAs (ncRNAs) and MicroRNAs (miRNAs)
The discovery that the majority of the human genome is not transcribed into protein [1], expanded
our initial definition of a gene to include non-coding RNAs. Unlike the traditional definition of a gene,
a DNA sequence that is transcribed into RNA then translated to produce a functional protein product,
non-coding RNAs (ncRNAs) are functional RNA molecules that are not translated into protein. While
the function of many of the ncRNAs in the genome is not yet determined, ncRNAs can generally
be separated into two different groups: infrastructural and regulatory. Infrastructural ncRNAs are
constitutively expressed and function within many cell homeostatic processes, such as splicing and
translation, and include species such as transfer RNA (tRNA), ribosomal RNA (rRNA), small nuclear
RNA (snRNA), and small nucleolar RNA (snoRNA). On the other hand, regulatory ncRNAs elicit
effects on other RNA molecules, and can be further classified based upon their size into short (<200 nt),
which includes microRNAs (miRNAs), small interfering RNAs (siRNAs), and Piwi-interacting RNAs
(piRNAs), and long (lncRNA, >200 nt) ncRNAs.
MicroRNAs (miRNAs) are a large family of ~21–22 nucleotide RNAs that negatively regulate
protein-coding gene expression post-transcriptionally in both metazoans and plants [2]. Canonically,
miRNAs are transcribed in the nucleus by RNA polymerase II [3] or III [4] into primary miRNA
(pri-miRNA), which range from hundreds to thousands of nucleotides long. Intronic miRNAs, located
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within a host gene, are transcribed using the same promoter as the primary transcript, while intergenic
miRNAs rely on their own promoters [5–7]. After transcription by RNA polymerase, pri-miRNAs
are then polyadenylated and capped. Pri-miRNA transcripts contain a stem-loop structure that
contains the mature miRNA sequences, which are cleaved via an RNase III type enzyme, Drosha,
and its binding partner DiGeorge syndrome critical region gene 8 (DGCR8) [8–10]. The resultant
stem-loop intermediates are termed precursor miRNA (pre-miRNA). Each pre-miRNA is then exported
to the cytosol via exportin-5 [11–13], and once in the cytosol is subjected to another microprocessing
event carried out by the RNase III enzyme Dicer. Dicer cleaves the pre-miRNA into an RNA duplex
(~22 nucleotides) containing the mature miRNA sequence [14–18]. In most cases, one strand of this
duplex is preferentially degraded, while the other is selected to be loaded into the RNA induced
silencing complex (RISC) [19,20]. Once loaded into the RISC, the mature miRNA provides the binding
specificity for the complex, and the complex elicits the negative regulation of the target mRNA. A
figure graphically describing the canonical miRNA biogenesis pathway is shown in Figure 1. It should
also be noted that recent research has identified several miRNAs that are formed by bypassing key
steps in the canonical miRNA biogenesis pathway [21,22]. However, these non-canonical miRNAs still
function like the canonical miRNAs.
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Figure 1. anonical iR biogenesis path ay. iR s are transcribed in the nucleus via their
o n pro oters or host gene pro oters by R A poly erase II or III, for ing the pri ary iR A
transcripts which can range from hundreds to thousands of nucleotides long. Pri-miRNA transcripts
are polyadenylated and capped, then subjected to a microprocessing cleavage event by an RNase III
type enzyme, Drosha, and its binding partner DiGeorge syndrome critical region gene 8 (DGCR8) to
form a 60–120 nucleotide long precursor miRNA transcript (pre-miRNA). After the cleavage event,
pre-miRNAs are then exported out of the nucleus by exportin-5 to cytoplasm and again subjected to
a microprocessing event by another RNase II enzyme, Dicer, to form a miRNA duplex. Unwinding
of the miRNA duplex occurs and one strand is usually degraded, while the other is loaded into the
RNA induced silencing complex (RISC). Once loaded, the RISC searches for targets of the miRNA in
the genome. Once bound to a target mRNA, the RISC may induce negative expression of the mRNA
by three ways: 1) mRNA destabilization and degradation, 2) mRNA translational inhibition, or 3)
mRNA cleavage. The path at which the mRNA is regulated depends upon multiple factors of the
mature miRNA.
Although exceptions have been found, miRNAs typically elicit their inhibitory effects by base
pairing with the 3′ untranslated regions (3′-UTR) of target mRNAs through their seed sequence. The
seed sequence is the second to eighth nucleotide region at the 5′ end of the mature miRNA, and is
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primarily responsible for determining the specificity of the miRNA to its mRNA. Although the seed
sequence is critical for miRNA-loaded RISC recognition of target mRNA, the overall miRNA:mRNA
complementarity also impacts binding efficiency [2,23]. For example, a recent study demonstrated that
the 3′ end of the miRNA itself is critical in determining target recognition in vivo [24]. In addition,
many of the sites that match the miRNA seed sequence in the 3′UTR are preferentially conserved [25],
suggesting conserved regulatory functions for miRNAs. Once bound, miRNA base pairing can drive
mRNA destabilization and degradation, translational inhibition, or direct mRNA cleavage [26–29].
While mRNA destabilization and degradation as well as translation inhibition are both common, direct
mRNA cleavage occurs in rare cases and requires more extensive base pairing [28,29].
Since miRNAs can target multiple genes and can share their seed sequence with other miRNAs, it
is predicted that miRNAs can target over half of the human genome [5,25,30]. Therefore, miRNAs
are implicated in almost all cellular functions. An increasing wealth of knowledge now exists linking
miRNA dysfunction to cancer initiation and progression [31–33]. Since epigenetics has recently emerged
as an important factor in driving cancer initiation and progression, microRNAs likely are involved in
regulating the DNA and epigenetic machinery. Indeed, Dicer-specific ncRNA (miRNA and/or siRNA)
is necessary to form heterochromatin [34] and accumulate heterochromatin-specific proteins [35], and a
growing body of evidence demonstrates that miRNAs directly target and negatively regulate important
epigenetic machinery in breast and other cancers. We understand that miRNA expression has been
shown to be regulated by epigenetic mechanisms and this is reviewed elsewhere [36,37]. The findings
from current studies strongly suggest that miRNAs only indirectly regulate epigenetics by regulating
chromatin- and histone-modifying enzymes. This review will focus on the epigenetic machinery and
the miRNAs that have been shown to target this machinery in breast cancer.
2. The Epigenome and Its Regulators
Epigenetics refers to the heritable changes in gene expression without a change in the DNA
sequence itself [38]. Rather, they depend on the alteration of other properties such as DNA methylation,
histone modification patterns and ncRNAs, which are inherited through cell divisions. Although most
histone modifications have not yet been shown to be meiotically heritable, some studies suggest that
in males, histone-bearing nucleosomes are retained throughout spermatogenesis and therefore some
epigenetic modifications may be preserved across generations [39–41]. Epigenetic modifications can
broadly be classified into the following groups, and a table of known epigenetic regulators can be
found in Table 1.
2.1. DNA Methylation and Demethylation
In mammals, the primary epigenetic tag found on DNA is a stable but reversible, covalent
attachment of a methyl group to the C-5 position of the cytosine ring, converting it to a 5-methylcytosine
(5mC) [42]. The predominant target for DNA methylation are clusters of CpG nucleotides, which are
frequently associated with gene promoters [43], and methylation of promoter CpGs is almost always
associated with gene silencing. However, DNA methylation can also occur in the gene body leading to
increased gene expression in dividing cells [44,45]. In normal cells, DNA methylation predominantly
occurs in highly repetitive genomic regions [46] and a balance is important for normal development
and functioning. However, dysregulation of methylation drives aberrant gene expression and can
contribute to disease. Indeed, dysfunctional hypo- and hypermethylation of genes is a frequent and
early event in breast cancer, and correlates with disease severity and outcome [47–49].
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Table 1. Mammalian epigenetic modifiers.
Function Enzyme (Alias)
DNA methyltransferase
DNMT1 DNMT3B
DNMT2 DNMT3L
DNMT3A
DNA demethylases
TET1
TET2
TET3
Histone methyltransferase
KMT1A (SUV39H1) KMT3E (SMYD3)
KMT1B (SUV39H2) KMT3F (NSD3)
KMT1C (EHMT2) KMT3G (NSD2)
KMT1D (EHMT1) KMT4 (DOT1L)
KMT1E (SETDB1) KMT5A (SETD8)
KMT1F (SETDB2) KMT5B (SUV420H1)
KMT2A (MLL) KMT5C (SUV420H2)
KMT2B (MLL2) KMT6A (EZH2)
KMT2C (MLL3) KMT6B (EZH1)
KMT2D (MLL4) KMT7 (SETD7)
KMT2E (MLL5) KMT8A (PRDM2)
KMT2F (SETD1A) KMT8B (PRDM9)
KMT2G (SETD1B) KMT8C (PRDM6)
KMT2H (ASH1L) KMT8D (PRDM8)
KMT3A (SETD2) KMT8E (MECOM)
KMT3B (NSD1) KMT8F (PRDM16)
KMT3C (SMYD2) SMYD4 (ZMYND21)
KMT3D (SMYD1)
Histone demethylase
KDM1A (LSD1) KDM5B (JARID1B)
KDM1B (LSD2) KDM5C (JARID1C)
KDM2A (FBXL11) KDM5D (JARID1D)
KDM2B (FBXL10) KDM6A (UTX)
KDM3A (JMJD1A) KDM6B (JMJD3)
KDM3B (JMJD1B) KDM6C (UTY)
KDM3C (JMJD1C) KDM7A (JHDM1D)
KDM4A (JMJD2A) KDM7B (PHF8)
KDM4B (JMJD2B) KDM7C (PHF2)
KDM4C (JMJD2C) KDM8 (JMJD5)
KDM4D (JMJD2D) JMJD6
KDM4E (JMJD2E) PADI4
KDM4F (JMJD2F) NO66
KDM5A (JARID1A)
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Table 1. Cont.
Function Enzyme (Alias)
Histone acetyltransferase
KAT1 (HAT1) KAT7 (HBO1, MYST2)
KAT2A (GCN5) KAT8 (hMOF, MYST1)
KAT2B (PCAF) KAT9 (ELP3)
KAT3A (CREBBP) KAT12 (GTF3C4)
KAT3B (EP300) KAT13A (NCOA1)
HAT4 (NAA60) KAT13B (NCOA3)
KAT4 (TAF1) KAT13C (NCOA2)
KAT5 (TIP60) KAT13D (CLOCK)
KAT6A (hMOZ, MYST3) KAT14 (CRP2BP)
KAT6B (hMORF, MYST4) MCM3AP (GANP)
Histone deacetylase
HDAC1 HDAC10
HDAC2 HDAC11
HDAC3 SIRT1
HDAC4 SIRT2
HDAC5 SIRT3
HDAC6 SIRT4
HDAC7 SIRT5
HDAC8 SIRT6
HDAC9 SIRT7
2.1.1. DNA Methyltransferases
DNA methylation is regulated by a family of DNA methyltransferases (DNMTs), of which three
catalytically active DNMTs have been identified in mammals: DNMT1, DNMT3a, and DNMT3b.
DNMT3a and DNMT3b are both thought to be responsible for establishing the pattern of methylation
de novo [50]. Due to their de novo activity, much of the research on DNMT3a/b and miRNAs focuses
on regulation of DNMT3a/b downstream regulated targets. However, miRNA direct targeting of
DNMT3a/b has revealed controversial results in cancer progression, with some showing oncogenic [51]
and others a tumor suppressor function [52,53]. Additionally, it has been shown that miR-148 directly
targets only one of the three splice variants of DNMT3b (Dnmt3b1) [54], suggesting that splice
variant-specificity of miRNAs is a field of research that needs to be further explored. Although DNMT1
also has de novo activity [55], DNMT1 typically thought of as required for maintaining the pattern
of DNA methylation during DNA replication [56,57]. Methyl-binding domain (MBD) proteins are
the primary candidates for the readout of DNA methylation [58,59] because of their ability to bind to
methylated CpG sites, and are thought to induce gene silencing by recruiting chromatin remodelers,
histone deacetylases, and methylases to methylated DNA [60,61].
2.1.2. DNA Demethylases
Despite its stability, DNA methylation can be reversed and this can occur as either an active or
passive process [62]. Passive DNA demethylation can occur when there is a lack of functional DNA
methylation machinery, which results in the failure to keep 5mC tags on the newly synthesized DNA
strand and thus dilutes 5mC following replication. On the other hand, active DNA demethylation
is mediated by the ten eleven translocation (TET) family of proteins: TET1, TET2, and TET3. TET
proteins facilitate DNA demethylation by two different mechanisms: i) physical binding to DNA to
prevent unwanted DNA methylation [63,64], and ii) enzymatic removal of the methyl group from
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5mC. The mechanism for demethylation includes multiple oxidation steps which are all mediated
by TET proteins: i) oxidation of 5mC to 5-hydroxymethylcytosine (5hmC), ii) oxidation of 5hmC
to 5-formylcytosine (5fC), and iii) oxidation of 5fC to 5-carboxylcytosine (5caC) [65–67]. Although
dilution of these demethylation intermediates can occur through replication, a demethylated cytosine
typically occurs through thymine DNA glycosylase (TDG)-mediated base excision followed by base
excision repair (BER) of 5caC and 5fC [68,69]. Generally, miRNAs that target the TET family of DNA
demethylases act as oncogenic miRNAs (oncomiRs) [70–72], likely due to the reactivation of silenced
oncogenes. Additionally, some evidence exists demonstrating that DNMT3a and DNMT3b also are
important in DNA demethylation of promoters [73,74], suggesting an increased complexity, and a
possibility of DNMT targeting miRNAs, in the mechanism of DNA demethylation.
2.2. Histone Modifications
Chromatin architecture may be transmissible to daughter cells [75], therefore histones and
modifications to histones are likely candidates for carriers of epigenetic information. Histones are the
protein that DNA is wrapped around within chromatin, which consists of an octomeric globular core
(H2A, H2B, H3, and H4) and these cores are connected to each other by a short stretch of linker DNA,
which gives the “beads on a string” structure. The linker histone H1 binds to the entry and exit sites of
DNA from the histone core, which stabilizes higher-order chromatin structures [76]. Each monomer of
the core, as well as the H1 linker histone, contains a tail which can be targeted for histone modifications.
Histone modifications are covalent post-translational modifications to histone proteins which alters
chromatin structure or recruits histone modifiers. Histone modifications that regulate epigenetics
include methylation and acetylation, which are typically accompanied by the epigenetic regulators of
the trithorax (TrxG) and polycomb (PcG) group of proteins [77,78]. These epigenetic modifications
coordinate DNA accessibility, and thus regulate gene expression throughout development and in
breast cancer. Therefore, it is thought that histone methyl- and acetyl-modifying enzymes represent
promising therapeutic targets in breast cancer [79–81]. Figures showing which histone tail residues are
acetylated and methylated, and which enzyme performs each modification is shown in Figures 2 and 3.
2.2.1. Histone Methyltransferases
In addition to DNA methylation, histones can also be methylated. Assessment of genome-wide
histone methylation marks show that lysine and arginine residues are particularly enriched for
methylation, and whereas DNA methylation is associated with silencing, histone methylation is
correlated with both silencing and activation [82]. The two major families of histone methyltransferases
(HMTs) are lysine methyl transferases (KMTs) and protein arginine methyltransferases (PRMTs) [83],
which methylate their respective residues.
Histone lysine residues can either be mono-, di-, or trimethylated and are catalyzed by two main
KMT families: SET domain containing methyltransferases and the DOT1 family [84]. One of the most
well-known KMTs is KMT6A (also known as EZH2). EZH2 is highly abundant in proliferative cells,
and establishes repressive marks on PcG target genes to exert its oncogenic potential [85]. Due to
its well-known role in oncogenesis, many studies have shown that miRNAs can directly target and
negatively regulate KMT6A expression to abrogate its effects on cancer progression [86–89].
In contrast to histone lysine residues, histone arginine residues can only be mono- or
dimethylated [84]. These PRMTs can also be divided into type I and type II PRMTs, where type I
PRMTs form mono- and asymmetric dimethylarginines and type II PRMTs form mono- and symmetric
dimethylarginines [84]. Although both KMTs and PRMTs methylate histone tail residues, most research
has focused on miRNA regulation of KMTs. Research to date generally supports the fact that miRNAs
act as tumor suppressors by decreasing KMT expression.
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Figure 2. Writer and erasers for histone methylation. A schematic representation of a nucleosome and
the known principal lysine (K) and arginine (R) residue methylation sites on the H1.4, H2A, H3, and
H4 tails. The number associated with the lysine or arginine residue represents that residues location on
the depicted tail (i.e., “K5” on histone H2A tail refers to the lysine residue at amino acid 5 on the H2A
tail). The writers (lysine or arginine methyltransferases, black text) and the erasers (lysine and arginine
demethylases, red text) for each methylation site are also shown with their known methylation state
specificities: monomethylation: 1; dimethylation: 2; trimethylation: 3; asymmetrical dimethylation: 2a;
symmetric dimethylation: 2s. Arrows near the DNA indicate direction that the DNA wraps around
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2.2.2. Histone Demethylases
Histone demethylation is carried out by two different classes of histone demethylases (HDMs):
amine-oxidase type lysine-specific demethylases (LSDs) and the JumonjiC (JMJC) domain containing
histone demethylases. Although both of these classes remove methyl groups from histones, they differ
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in their catalytic mechanism. LSD demethylases are flavin adenine dinucleotide (FAD)-dependent
allowing these to remove methyl groups from mono- and di-, but not trimethylated lysines [84]. While
JMJC domain containing demethylases are iron and 2-oxoglutarate (2-OG)-dependent enzymes, and
can demethylate all three methyl lysine states as well as arginine residues [84,90]. The specificity of
these HDMs for methyl groups is often determined by its incorporation within different complexes.
Demethylation of targets by HDMs typically results in enhanced expression of genes that drive
proliferation, migration, and invasion [91–94], which suggests that miRNA regulation of these proteins
is important in inhibiting cancer cell survival and progression.
2.2.3. Histone Acetyltransferase
Histone acetylation is central in regulation of DNA accessibility for transcription [95,96].
Acetylation of histones primarily occurs on the histone tails and controls gene expression through two
mechanisms: i) direct effect on the stability of the histone:DNA complex and ii) creating docking sites
for regulatory complexes [97,98]. Two groups of histone acetyltransferases (HATs) exist, type A and
type B. Type A HATs acetylate histones and other chromatin-associated proteins in the nucleus, and
type B HATs acetylate newly synthesized histones in the cytosol [99,100]. Although both types acetylate
histones, type B HATs have no direct influence on transcription [100]. Type A HATs can be split into
five families: GNAT, MYST, p300/CBP, nuclear receptor coactivators, and general transcription factors.
Since most HATs exist within multiprotein complexes, it is the context in which the HATs exist that
determines the acetylation specificity, and these complexes are determined upstream through changes
within the cellular environment. Much of the work on miRNA regulation of HATs has focused on
two specific HATs: the NCOA (KAT13) family, nuclear transcriptional coactivators, and p300 (KAT3B),
a well-known tumor suppressor [101]. Therefore, miRNA regulation in HAT-driven processes has
elucidated both oncogenic and tumor suppressor functions for miRNAs.
2.2.4. Histone Deacetylases
Histone deacetylases (HDACs) are devoted to the removal of acetyl groups from lysine residues.
HDACs exist in multi-unit protein complexes and are typically thought to repress transcription. Based
upon their structural homology to yeast HDACs, human HDACs can be divided into four classes:
Class I Rpd3-like proteins, Class II Hda1-like proteins, Class III Sir2-like proteins, and a single Class
IV protein [102]. Although divided into separate classes, class I, II and IV share a conserved zinc
ion-mediated catalytic mechanism to hydrolyze the bond of the acetylated lysine. However, Class
III HDACs use NAD+ as a reactant to deacetylate lysine residues. In addition to interactions with
histones, HDACs can also deacetylate non-histone proteins in breast and other cancers [103–105]. As in
HAT regulation, the role that miRNAs play in HDAC-mediated cellular functions yield both oncogenic
and tumor suppressor miRNAs. Although a majority of the research has yielded important functions
of miRNAs in HDAC-mediated drug resistance.
3. MicroRNAs Regulate the Machinery of the Breast Epigenome
In addition to being subjected to epigenetic regulation themselves through DNA and histone
modifications of their corresponding genes [36,37], miRNAs also play a more decisive role in chromatin
structure control and gene expression by directly targeting the post-transcriptional regulation of key
chromatin- and DNA-modifying enzymes. This subclass of miRNAs are also known as epi-miRs [106],
and can affect the epigenetic enzymes either directly or indirectly. This section will focus on miRNAs
that have been identified to directly bind to the 3′UTR of epigenetic machinery in breast cancer.
However, a full list of breast epi-miRs that have been shown to reduce epigenetic machinery mRNA
and/or protein expression is shown in Table 2.
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Table 2. Epigenome regulators targeted by microRNAs in breast cancer.
microRNA miRNA acts as a Tumor Suppressor orOncogenic miRNA (OncomiR) Target (alias) Function of Target in Citation Reference
miR-7 Tumor suppressor miRNA KMT1E (SETDB1) Promotes STAT3 expression which drives c-MYC, TWIST, and miR-9expression in BCSCs [107]
miR-7 Tumor suppressor miRNA KMT5A (SETD8) Drives DNA double stranded breaks and promotes DNA repair [108]
miR-10b OncomiR HDAC4 Promotes tamoxifen sensitivity; enhances tamoxifen-induced apoptosis [109]
miR-17 Tumor suppressor miRNA KAT13B (NCOA3) Promotes taxol resistance by increasing Bcl-2 expression [110]
miR-17-5p Tumor suppressor miRNA KAT13B (NCOA3) Accelerates proliferation; enhances E2F1- and estrogenreceptor-mediated gene expression [111]
miR-17-5p Tumor suppressor miRNA KAT13B (NCOA3) Accelerates proliferation; enhances estrogen receptor-mediated geneexpression [112]
miR-20b Tumor suppressor miRNA KAT13B (NCOA3) Promotes taxol resistance by increasing Bcl-2 expression [110]
miR-22 OncomiR HDAC4 Transcriptional repressor of p21 and p27; Regulates sensitivity tofulvestrant [113]
miR-22 OncomiR KAT5 (TIP60) Involved in the inhibition of EMT; Decreases cell migration andinvasion [114]
miR-22 Tumor suppressor miRNA KDM7B (PHF8) Promotes EMT; Binds to transcriptional start site of, and activates,SNAI1; Drives cell proliferation, migration, and tumor growth [115]
miR-22 Tumor suppressor miRNA SIRT1 Promotes proliferation, migration, and invasion; Inhibits senescence [116,117]
miR-22 OncomiR TET1 Promotes global 5hmC levels [70]
miR-22 OncomiR TET2 Promotes global 5hmC levels; Inhibits cell migration, EMT, andmammosphere formation; Promotes miR-200 family expression [70]
miR-22 OncomiR TET3 Promotes global 5hmC levels; Inhibits cell migration, EMT, andmammosphere formation; Promotes miR-200 family expression [70]
miR-23a Tumor suppressor miRNA KDM4A (JMJD2A) Promotes transient site-specific copy gains; Drives drug resistancethrough expression of CKS1B [92]
miR-23b Tumor suppressor miRNA KDM4A (JMJD2A) Promotes transient site-specific copy gains [92]
miR-25 OncomiR KAT3B (EP300) Inhibits EMT through increased E-cadherin expression; Blocks drug-and irradiation-induced senescence [118]
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Table 2. Cont.
microRNA miRNA acts as a Tumor Suppressor orOncogenic miRNA (OncomiR) Target (alias) Function of Target in Citation Reference
miR-26a Tumor suppressor miRNA KMT6A (EZH2) Inhibits apoptosis; Promotes anchorage-independent growth andtumorigenesis [87]
miR-26b Tumor suppressor miRNA KMT6A (EZH2) Promotes tumor aggressiveness and the inflammatory phenotype [88]
miR-29a OncomiR TET1 Inhibits cell proliferation, migration, and EMT [71]
miR-29b OncomiR TET1 Inhibits cell proliferation, anchorage-independent growth, migration,and EMT; Binds to the promoter region of the ZEB2 [72]
miR-29b-5p Tumor suppressor miRNA KAT13B (NCOA3) Accelerates proliferation; enhances estrogen receptor-mediated geneexpression [112]
miR-34a Tumor suppressor miRNA HDAC1 Deacetylates HSP70 K246; Promotes cancer cell survival and drugresistance by inhibiting autophagic cell death [119]
miR-34a Tumor suppressor miRNA HDAC7 Deacetylates HSP70 K246; Promotes cancer cell survival and drugresistance by inhibiting autophagic cell death [119]
miR-34a Tumor suppressor miRNA SIRT1 Promotes expansion of BCSCs; Drives tumor growth [120]
miR-92b Tumor suppressor miRNA KMT6A (EZH2) Blocks rapamycin-induced autophagy; Enhances cell viability andinvasion [89]
miR-93 OncomiR KAT3B (EP300) Inhibits EMT through increased E-cadherin expression; Blocks drug-and irradiation-induced senescence [118]
miR-101 Tumor suppressor miRNA KMT6A (EZH2) Drives a metastatic tumor phenotype, oncogenic gene expression, andcell invasion [121]
miR-106a Tumor suppressor miRNA KAT13B (NCOA3) Accelerates proliferation; enhances estrogen receptor-mediated geneexpression [112]
miR-106b Tumor suppressor miRNA KAT13B (NCOA3) Accelerates proliferation; enhances estrogen receptor-mediated geneexpression [112]
miR-106b OncomiR KAT3B (EP300) Inhibits EMT through increased E-cadherin expression; Blocks drug-and irradiation-induced senescence [118]
miR-125a-5p Tumor suppressor miRNA HDAC4 Promotes cell proliferation, migration, and invasion; Decreasesexpression of HDAC5 and HDAC7 [122]
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Table 2. Cont.
microRNA miRNA acts as a Tumor Suppressor orOncogenic miRNA (OncomiR) Target (alias) Function of Target in Citation Reference
miR-125a-5p Tumor suppressor miRNA HDAC5
Drives cell proliferation, migration, and invasion; Decreases apoptosis
by deacetylating RUNX3 and reduces RUNX3-p300 complex binding to
target promoters
[123]
miR-128 Tumor suppressor miRNA SIRT1
Deacetylates p53 and suppresses its transcriptional targets; Increases
Akt signaling; Protects against apoptosis by decreasing PUMA
expression
[124]
miR-137 Tumor suppressor miRNA KAT13A (NCOA1) Accelerates proliferation; Decreases cell viability [112]
miR-137 Tumor suppressor miRNA KAT13B (NCOA3) Accelerates proliferation; enhances estrogen receptor-mediated geneexpression [112]
miR-137 Tumor suppressor miRNA KAT13C (NCOA2) Accelerates proliferation; Decreases cell viability [112]
miR-137 Tumor suppressor miRNA KDM4A (JMJD2A) Promotes transient site-specific copy gains [92]
miR-137 Tumor suppressor miRNA KDM5B (JARID1B) Drives cell proliferation and migration [94]
miR-138 Tumor suppressor miRNA KDM5C (JARID1C) Drives cell proliferation [94]
miR-138 Tumor suppressor miRNA KDM6B (JMJD3) Promotes cell proliferation, invasion, and EMT through H3K27me3demethylation [125]
miR-138 Tumor suppressor miRNA KMT6A (EZH2) Drives cell invasion EMT, and primary tumor growth [126]
miR-143 Tumor suppressor miRNA DNMT3A Accelerates cell proliferation and anchorage-independent growth;Hypermethylates PTEN and TNFRSF10C [52]
miR-148 n/a DNMT3B n/a; Only studied binding of miR-148 of different DNMT3B splicevariants in normal and cancer cells [54]
miR-148a Tumor suppressor miRNA DNMT1
Promotes cell proliferation, colony formation, and tumor angiogenesis;
Drives IGF-IR and IRS1 expression, and promotes Akt and ERK
signaling by hypermethylating miR-148a; Suppresses ER-α expression
[127,128]
miR-152 Tumor suppressor miRNA DNMT1
Promotes cell proliferation, colony formation, and tumor angiogenesis;
Drives IGF-IR and IRS1 expression, and promotes Akt and ERK
signaling by hypermethylating miR-152
[127]
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Table 2. Cont.
microRNA miRNA acts as a Tumor Suppressor orOncogenic miRNA (OncomiR) Target (alias) Function of Target in Citation Reference
miR-185 Tumor suppressor miRNA DNMT1 Drives cell proliferation; Silences BRCA1 expression byhypermethylation [129]
miR-199 Tumor suppressor miRNA KMT6A (EZH2) Accelerates cell proliferation and promotes invasion [86]
miR-200a Tumor suppressor miRNA SIRT1
Promotes cellular transformation, anchorage-independent growth and
migration; Binds to miR-200a promoter and recruits DNMT1, 3A, and
3B to suppress expression
[130]
miR-200b Tumor suppressor miRNA DNMT3A Binds, along with c-MYC, to the miR-200b promoter to silenceexpression and drive EMT [53]
miR-200b Tumor suppressor miRNA KAT13B (NCOA3) Accelerates proliferation; enhances estrogen receptor-mediated geneexpression [112]
miR-200b Tumor suppressor miRNA SUZ12
Promotes formation and maintenance of mammospheres, as well as
tumor growth and the maintenance of CSCs through H3K27me3 and
recruitment of PcG suppression of E-cadherin
[131]
miR-200c Tumor suppressor miRNA KAT13B (NCOA3) Accelerates proliferation; enhances estrogen receptor-mediated geneexpression [112]
miR-211-5p Tumor suppressor miRNA SETBP1 Promotes cell proliferation, invasion, and migration, as well asmetastasis [132]
miR-214 Tumor suppressor miRNA KMT6A (EZH2) Accelerates cell proliferation and promotes invasion [86]
miR-221 OncomiR DNMT3B Inhibits stemness by repressing Nanog and Oct3/4 expression [51]
miR-222 OncomiR DNMT3B Inhibits stemness by repressing Nanog and Oct3/4 expression [51]
miR-340 Tumor suppressor miRNA KMT6 (EZH2) Drives cell proliferation, invasion, migration, and induces apoptosisvia DNMT1 expression and decreased miR-200a/b expression [133]
miR-342 OncomiR DNMT1 Binds to ID4 promoter for normal breast function and development [134]
miR-381-3p Tumor suppressor miRNA KMT1E (SETDB1) Drives cell proliferation, cell cycle progression and migration;Accelerates primary tumor growth [135]
miR-448 Tumor suppressor miRNA KDM5B (JARID1B)
Enhances proliferation, anchorage-independent growth, migration,
invasion, and promotes a stem-like phenotype via induction of lncRNA
MALAT1
[93]
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Table 2. Cont.
microRNA miRNA acts as a Tumor Suppressor orOncogenic miRNA (OncomiR) Target (alias) Function of Target in Citation Reference
miR-491-5p Tumor suppressor miRNA KDM4B (JMJD2B) Suppresses estrogen receptor-mediated signaling and cell proliferation [136]
miR-502 Tumor suppressor miRNA KMT5A (SETD8) Promotes cell cycle progression, migration, invasion, and EMT [137]
miR-519d Tumor suppressor miRNA KAT13B (NCOA3) Accelerates proliferation; enhances estrogen receptor-mediated geneexpression [112]
miR-590-3p Tumor suppressor miRNA SIRT1 Drives cell survival; Inhibits apoptosis; Prevents acetylation andactivation of p53 [138]
miR-708 Tumor suppressor miRNA KDM1A (LSD1) Promotes cell proliferation and invasion [91]
miR-1307-3p OncomiR SMYD4 Suppresses cell proliferation and anchorage-independent growth;Inhibits tumor formation [139]
miR-1915-3p Tumor suppressor miRNA KMT2F (SETD1A)
Drives estrogen receptor-mediated signaling through H3K4
methylation; Enhances cell proliferation and migration; Suppresses
apoptosis
[140]
miR-3666 Tumor suppressor miRNA SIRT7 Promotes cell proliferation; Inhibits apoptosis [141]
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3.1. Targeting of DNA Methyltransferases
Since DNA methylation is the primary epigenetic tag in mammals, it is not surprising that
miRNAs have been found to directly target the enzymes that catalyze these tags. For example, Ng
et al. found that miR-143 directly targets DNMT3A in breast cancer [52]. Mechanistically, direct
targeting of DNMT3A by miR-143 results in a decrease in promoter methylation-specific silencing of the
tumor suppressors phosphatase and tensin homolog (PTEN) and tumor necrosis factor (TNF) receptor
superfamily member 10c (TNFRSF10C). This results in decreased growth and anchorage-independent
colony formation of breast cancer cells [52].
Although most well known for their role in regulating epithelial-mesenchymal transition
(EMT) [33], the miR-200 family also can regulate the methylation machinery to regulate triple
negative breast cancer (TNBC). Since the expression of the miR-200 family is suppressed in TNBC,
Pang and colleagues aimed to understand the epigenetic mechanisms underlying miR-200b repression
in TNBC [53]. They first found an inverse correlation between DNMT3A and miR-200b in TNBC breast
tissues, which suggests epigenetic modification of miR-200b expression. Indeed, both treatment of
TNBC cells with 5-aza-2′-deoxycytidine (DAC, a demethylating agent) and knockdown of DNMT3A
expression increased miR-200b expression by alleviating promoter methylation. They also found that
silencing of miR-200b is mediated by MYC binding to the promoter region of miR-200b and recruiting
DNMT3A. Interestingly, miR-200b was also found to directly target DNMT3A [53], suggesting a
complex feedback loop between DNMT3A and miR-200b. Overall, this feedback loop may be critical
for understanding the regulation of EMT in TNBC, and suggests that epigenetic silencing of the
miR-200 family is important in TNBC initiation and progression.
In addition to regulating growth and EMT through DMNT3A, epi-miRs can regulate stemness
of breast cancer cells. Roscigno and colleagues found that the epi-miR, miR-221, regulates the
stemness of breast cancer cells by directly targeting DNMT3B [51]. They first found that in breast
cancer stem cells (BCSCs) isolated from patients, miR-221 was significantly upregulated compared to
differentiated cells. Furthermore, enriching multiple breast cancer cell lines for stem cells in vitro not
only resulted in an increase in stemness markers, but also resulted in increased miR-221 expression,
suggesting that miR-221 is involved in regulating BCSCs. Indeed, overexpressing miR-221 increased,
and inhibiting decreased, mammosphere formation, stemness marker expression, and enrichment of
the CD24−/low/CD44+ stem cell population. Since stemness gene expression is primarily regulated by
methylation, this group also looked at the role of miR-221 in methylation. Interestingly, overexpression
of miR-221 reduces methylation of the CpG islands located within the promoters of stemness genes
Nanog and Oct3/4. Mechanistically, Roscigno et al. determined that miR-221 directly targets DNMT3B,
and expression levels of DNMT3B is inversely associated with miR-221 expression [51]. Together, this
data demonstrated that miR-221 contributes directly to silencing of DNMT3B, leading to the aberrant
expression of stemness genes.
3.2. Targeting of DNA Demethylases
MicroRNAs also target DNA demethylases, mediated by the ten eleven translocation (TET) family,
which can lead to dysregulation of genes involved in critical cellular functions. Two members of the
miR-29 family (miR-29a [71] and miR-29b [72]) have independently been shown to directly target TET1
in breast cancer. In addition to targeting TET1, both of these studies demonstrated that expression of the
miR-29 family member promoted proliferation and EMT in vitro. However, in breast tissues miR-29a
expression was found to be increased in ER(−) samples [71] and miR-29b decreased in all samples [72]
compared to normal adjacent tissue. This discrepancy may be due to separation of samples by subtype
in the previous study and no separation in the latter study. Additionally, it is not uncommon to have
members of the same family differentially expressed in different cancer types and even within the same
cancer [33,142], which adds complexity to our understanding of these disease states.
In addition to the miR-29 family, miR-22 has also been shown to directly target TET1 [70]. Stable
expression of miR-22 in normal breast and breast cancer cells enhanced migration and induced EMT
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both in vitro and in vivo settings. As the miR-200 family is involved in regulating EMT, Song and
colleagues next looked at whether miR-22 could affect the expression of the miR-200 family members.
They found that miR-22 could repress miR-200a and miR-200c expression in both normal mammary
epithelial cells and mouse mammary epithelium. This is accomplished by miR-22 stimulating promoter
hypermethylation through targeting of TET family members. Although a luciferase reporter assay
was only performed for TET2, miR-22 was also shown to regulate TET1 and TET3 mRNA and protein
levels [70]. This demonstrates that miR-22 functions as an epigenetic modifier and promotes EMT,
stemness, and metastasis in breast cancer.
3.3. Targeting of Histone Methyltransferases
Enhancer of zeste homolog 2 (EZH2), is the catalytic component of the polycomb repressive
complex 2 (PRC2) and is highly expressed in breast cancer. Due to its well-known role in many
cell fate decisions [143], many microRNAs have been shown to directly target EZH2 to modulate
its expression in breast cancer [86,87,89,121,126,133]. In addition to changes in cell proliferation,
anchorage-independent growth, migration, invasion, autophagy and apoptosis, reduction of EZH2
expression concomitantly reduced global H3 methylation levels. Interestingly, stable expression of
three of these miRNAs (miR-101, miR-138, and miR-340) not only reduced EZH2, but also affected the
expression of epigenetically regulated miRNAs [121,126,133]. However, in all cases reduction of EZH2
by miRNAs inhibited tumor growth and metastasis in mouse models, suggesting that these miRNAs
act as tumor and metastasis suppressors, and demonstrate that EZH2 is an important therapeutic
target in breast cancer.
In breast cancer, both SETDB1 and SETD8 are directly targeted by miR-7 [107,108]. Expression of
miR-7 was shown to suppress EMT in both more differentiated and breast cancer stem cells. Zhang et al.
demonstrated that by targeting SETDB1, the expression of the SETDB1 downstream effector STAT3 is
also reduced [107]. Since, STAT3 promotes the expression of TWIST and TWIST is physically associated
with SETD8 [144], miR-7 seems to regulate multiple epigenetic regulators within the same pathway.
Additionally, miR-7 promotes DNA damage and STAT3 activation is cytoprotective, which suggests
that miR-7 also regulates apoptosis through binding to epigenetic regulators. Therefore, miR-7 is
heavily involved in regulating multiple pathways involved in breast cancer progression.
3.4. Targeting of Histone Demethylases
MiRNAs also directly regulate the expression levels of histone demethylases (KDMs) in breast
cancer. The main member of the amine-oxidase type lysine-specific demethylases, KDM1A (also known
as LSD1), is a direct target of miR-708 in triple negative breast cancer [91]. Increased expression of
miR-708 in MDA-MB-231 cells resulted in a reduction in cell growth and invasion, which was rescued by
stable expression of KDM1A. Furthermore, Shao et al. also found that KDM7B (or PHF8) has oncogenic
effects on breast cancer cells [115]. Expression of KDM7B promoted mammosphere formation and
EMT by reducing the methylating marks near the transcription start site of SNAI1. However, stable
expression of miR-22 was able to abrogate these phenotypes and regulate the expression of KDM7B. In
addition to KDM1A and KDM7B, many members of the Jumonji (JMJC) domain containing family are
also directly targeted by miRNAs through binding sites in their 3’UTR; miR-491-5p targets KDM4B
(JMJD2B) [136], miR-137 targets KDM5B (JARID1B) [94], and miR-138 targets KDM5C (JARID1C) [94].
Overall, these studies demonstrate that each of the miRNAs elicit tumor suppressor effects through
direct binding and inhibition of histone demethylase expression.
3.5. Targeting of Histone Acetyltransferases
Different studies have shown that the histone acetyltransferase KAT13B (NCOA3) is targeted
by multiple miRNAs in breast cancer [110–112]. The study by Eedunuri and colleagues not only
demonstrated that KAT13B protein expression is modulated by miR-137, but also that miR-137 reduced
protein expression of the other family members KAT13A (NCOA1) and KAT13C (NCOA2) suggesting
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that miR-137 targets multiple members of the KAT13 family [112]. KAT13B can act as a coactivator
for nuclear receptors (such as the estrogen receptor) which can modify the chromatin environment
to facilitate gene expression. Consistent with this, inhibition of KAT13B by miR-17-5p was not only
able to severely limit ER-dependent cell growth, but it also reduced IGF-1-mediated growth [111].
Additionally, increased expression of KAT13B can also modify chromatin to drive expression of
chemoresistance to common therapeutics such as taxol [110]. These studies suggest that loss of miRNA
regulation can promote epigenetic mechanisms that feed cancer cell progression.
In addition to targeting the coactivators of nuclear receptors to change chromatin structure and
gene expression, miRNAs also modulate histone acetyltransferases to epigenetically regulate EMT
downstream effectors. Recent works demonstrated that the miR-106b-25 cluster (miR-106b, miR-93,
and miR-25) and miR-22 target KAT3B [118] and KAT5 [114], respectively, in breast cancer. However,
in contrast to the above studies, by reducing levels of KAT3B and KAT5, these miRNAs promote the
expression of EMT markers and drive cell migration, invasion, and stemness. This suggests that, at
least for histone acetyltransferases, miRNA involvement in epigenetic mechanisms that control cancer
progression may be context and target dependent.
3.6. Targeting of Histone Deacetylases
HDAC protein levels are also modulated by several miRNAs in breast cancer. Both miR-34a and
miR-10b are involved in epigenetic regulation of treatment response of breast cancer by targeting
HDACs [109,119]. Wu and colleagues demonstrated that miR-34a does this, at least in part, by
inhibiting the deacetylation of lysine 246 on heat shock protein 70 (HSP70) [119]. Additionally, two
separate studies found that miR-125a-5p directly targets HDAC4 [122] and HDAC5 [123] to inhibit
multiple biological functions of breast cancer cells, such as apoptosis, growth, and motility. It was also
concluded that miR-125a-5p may have an application as a prognostic biomarker as serum levels of
miR-125a-5p correlated with tumor stage and lymph node status [122].
4. MicroRNA as Epigenetic Biomarkers and Therapeutic Targets
The epigenetic status of a tumor can strongly influence its behavior and aggressiveness [145–148],
suggesting that epigenetic markers can relate to clinical prognosis. Since the symptoms of a tumor often
do not present themselves until the primary tumor has progressed to invade the surrounding tissue
and because epigenetic changes occur very early in the transition to disease states, the use of epigenetic
biomarkers may provide an avenue for early detection and cancer prevention. Current efforts to
utilize epigenetic markers as a biomarker focus on histone and promoter methylation as a source for
prognostic information and predictive power [149]. Although miRNAs have been demonstrated as
highly tissue-specific biomarkers [150–152], the use of miRNAs as epigenetic biomarkers has been less
explored. Still, some studies have identified miRNA signatures containing some known epi-miRs
that correlate with patient outcome in breast cancer as well as overall risk, receptor expression, tumor
stage, and proliferation index [153–156]. Furthermore, single nucleotide polymorphisms (SNPs) in
the epi-miR binding site of the target mRNA contributing to early breast cancer development [157]
demonstrates that miRNAs show promise as epigenetic biomarkers.
In the clinic there are two strategies for epigenetic therapy: i) small molecules that inhibit the
epigenetic machinery (DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors
(HDACi). The treatment with DNMTi and/or HDACi has proven to be very beneficial for hematological
malignancies by turning on tumor suppressors that were silenced, but has controversial results for
solid tumors [158,159]. And ii) the manipulation of miRNA expression. Several direct and indirect
strategies are used to silence oncogenic miRNA and to express tumor suppressor miRNAs [160], and
the main advantages of using miRNAs as epigenetic therapeutics include the ability to affect multiple
pathways through the modulation of a single miRNA and that many of the hallmarks of cancer are
driven by miRNAs.
Cancers 2019, 11, 897 17 of 25
The use of miRNAs as an epigenetic treatment option is another promising avenue, and can be
used by itself or in combination with other therapies for breast cancer. However, the main challenges
of utilizing miRNAs in the clinical setting include overcoming poor intrinsic in vivo stability as well
as efficient and specific delivery of the miRNA to the tumor site. To address these deficiencies more
innovative delivery systems are needed. Both viral vectors and nonviral-based delivery systems
can be utilized to circumvent these barriers, however the toxicity and immunogenicity limit the
use of viral vectors in the clinic. Therefore, nonviral-based delivery systems gained traction as a
promising approach for therapeutic miRNA delivery because of the ease of control over composition,
manufacturing, modification, as well as a tolerance for cargo size and lower immunogenicity [161,162].
Particularly, cationic materials that condense negatively charged nucleic acids through electrostatic
interactions have shown the efficiency and specificity needed to successfully utilize miRNAs in the
clinic. However, due to a relatively lower efficiency than viral vectors, recent research has aimed to
improve this by modifying particle size and surface composition (for examples see [163–166]).
5. Conclusions and Future Perspectives
The recent studies demonstrating that miRNAs target the machinery of the breast epigenome
have enhanced our understanding of the crucial roles that miRNAs play in inherited gene expression.
A comprehensive list of currently validated epi-miRs and epi-miR targets in breast cancer is shown in
Table 2. Although direct targeting of some histone acetyltransferases were found to promote tumor
progression, the current data generally support the conclusion that epi-miRs act as tumor suppressors
in breast cancer.
Future work will need to identify the direct targets and mechanisms of epi-miRs. This will not
only expand the potential targets for therapy and increase their appeal as therapeutics and biomarkers
themselves, but also stand to determine in which context the miRNAs act as tumor suppressors
or oncogenes (for example miR-22 drives breast cancer progression by regulating the TET family
of DNA demethylases [70], but inhibits progression by targeting histone demethylases [115] and
deacetylases [116]). In addition to determining miRNA targets, we also need to determine the effects
that current epigenetic drugs have on the expression of miRNAs. Some studies suggest that epigenetic
drugs can exert antitumor effects by both turning on tumor suppressors as well as miRNAs that target
oncogenic mRNAs. Additionally, although significant advances have been made in our understanding
of how to deliver miRNA, more work needs to be done on how to efficiently and safely deliver miRNAs
to the target site. Thus, by completing this work we will have a better understanding of the role
that miRNAs play in regulating epigenetics, and will help to drive miRNAs into the clinic as the
next generation of cancer therapy. Overall, the wide range of interactions between miRNAs and the
epigenome in breast cancer provides new challenges and opportunities for the development of new
therapeutic strategies for the treatment of cancer.
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